Juvenile Idiopathic Arthritis
Single-Dose Prefilled Autoinjector for Actemra Approved
November 26, 2018Genentech announced that the FDA has approved ACTPen autoinjector for Actemra as a new formulation for adults with moderate to severe active RA.
Higher Biologic Drug Survival in JIA With Younger Age at Treatment Initiation
November 20, 2018Rates of biologic drug survival and suspension by remission were both higher in those who initiated biologic treatment at <16 years.
Rituximab May Be Effective in Children With Treatment-Resistant Juvenile Idiopathic Arthritis
November 19, 2018Rituximab may be an effective treatment option for many patients with juvenile idiopathic arthritis who did not respond to other therapies.
Determining Risk for New-Onset Uveitis in Juvenile Idiopathic Arthritis
November 08, 2018Researchers sought to quantify the annual incidence of new-onset uveitis following JIA diagnosis and identify associated risk factors.
Psychological Flexibility Improves Resilience in Children With Juvenile Idiopathic Arthritis and Their Parents
November 08, 2018Psychological flexibility in children with juvenile idiopathic arthritis and in their parents may represent resilience factors for dealing with pain and disability associated with the condition.
Canakinumab Treatment Led to Substantial Glucocorticoid Reduction in JIA
November 06, 2018Researchers evaluated the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis.
Original vs Expanded Disease Activity Scoring System in JIA Examined
October 02, 2018For a more precise assessment of disease activity and treatment effectiveness in individuals with JIA, inclusion of MCP joints should be considered in the scoring system.
Actemra SC Approved to Treat Active Systemic JIA
September 14, 2018The FDA has approved Actemra SC for the treatment of active systemic JIA alone or in combination with methotrexate in patients ≥2 years old.
Examining Gaps in Mental Health Care Among Youth With Juvenile Rheumatic Disease
August 15, 2018There is an unmet need for mental health interventions that address illness-related issues affecting youth with rheumatologic conditions.
Clinical Assessment of Juvenile Idiopathic Arthritis: Predicting Unfavorable Long-Term Outcomes
June 11, 2018Prediction models of outcomes in juvenile idiopathic arthritis have acceptable precision and require only readily available baseline variables.
Clinical Correlates of JIA Relapse After Biologic Therapy Discontinuation
May 16, 2018The investigators sought to evaluate the time patients were in remission after discontinuing biologic therapy for the treatment of JIA.
Actemra SC Approved to Treat Polyarticular Juvenile Idiopathic Arthritis
May 14, 2018The FDA has approved the subcutaneous formulation of Actemra for the treatment of active polyarticular juvenile idiopathic arthritis.
Depressive Symptoms Predict Future Pain, Disability in Adolescent JIA
May 11, 2018Baseline depressive symptoms were associated with pain and disability in adolescents with juvenile idiopathic arthritis.
Efficacy, Safety of Adalimumab vs Infliximab in JIA-Associated Uveitis
May 08, 2018Researchers evaluated the safety and efficacy of adalimumab and infliximab in the treatment of juvenile idiopathic arthritis-associated uveitis in patients treated for at least 2 years.
Treatment Targets in JIA: Comparing Definitions of Clinically Inactive Disease
April 30, 2018Investigators aimed to examine the use of treatment targets in juvenile idiopathic arthritis in terms of joint limitations, functional ability, psychosocial health, and pain levels.
Managing Uveitis in Juvenile Idiopathic Arthritis: Consensus-Based Recommendations
April 23, 2018The SHARE initiative has provided recommendations for the diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis.
Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis
April 20, 2018Results confirm that juvenile spondyloarthritis is characterized by its peripheral pattern at disease onset, with peripheral arthritis and enthesitis.
Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA
April 17, 2018The Epstein-Barr virus EBNA2 protein and many coclustering human transcription factors occupied nearly half of SLE risk loci.
Ultrasound Not Predictive of Disease Flares for Inactive Juvenile Idiopathic Arthritis
April 17, 2018Abnormal ultrasound findings were common in patients with juvenile idiopathic arthritis with clinically inactive disease.
Flare Risk Examined in Juvenile Idiopathic Arthritis After Anti-TNF Therapy Discontinuation
April 11, 2018Researchers sought to determine the predictors of disease flare after anti-TNF therapy discontinuation in children with polyarticular forms of juvenile idiopathic arthritis with sustained clinically inactive disease.
Examining the Role of Neutrophils in Systemic-Onset Juvenile Idiopathic Arthritis
March 05, 2018High neutrophil counts decreased after initiation of recombinant interleukin-1 receptor agonist therapy in systemic-onset juvenile idiopathic arthritis.
TNF Inhibitor Therapy Unlikely to Affect Malignancy Risk in Children
February 26, 2018Children with juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric plaque psoriasis had an increased incidence of childhood malignancies, regardless of TNFi exposure.
Juvenile Idiopathic Arthritis: Baseline Ultrasound Abnormalities May Predict Relapse
February 15, 2018Abnormality on an ultrasound examination significantly increased the risk for flare in patients with juvenile idiopathic arthritis.
Improving Pediatric Rheumatic Disease Care With Consensus-Based Treatment Plans
February 08, 2018The goal of consensus treatment plans is to drive a cycle of innovation and replacement that allows the addition of new treatments and the removal of unused or ineffective strategies.
More Severe Disease Found in Juvenile Myositis With Anti-NT5C1A Autoantibodies
February 07, 2018Autoantibodies that recognize cytosolic 5′-nucleotidase 1A were detected in about 25% of patients with juvenile myositis and juvenile idiopathic arthritis.
Choosing a Biologic Therapy for JIA: Etanercept vs Tocilizumab vs IL-1 Inhibitors
January 31, 2018Treatment response was most significant in patients taking either tocilizumab or an interleukin-1 inhibitor.
Adalimumab Effective in JIA-Associated Uveitis Unresponsive to Methotrexate
January 29, 2018Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
Juvenile Idiopathic Arthritis Disease Activity Low but Stable During Pregnancy
January 12, 2018An increase in disease activity 6 weeks postpartum suggests the need for tight follow-up of women with juvenile idiopathic arthritis.
Fluorescence Optical Imaging for Diagnosis of Pediatric Rheumatologic Conditions
November 30, 2017Chronic inflammatory rheumatologic diseases benefit from early anti-inflammatory treatment; however, interdisciplinary approaches may be necessary for identifying and managing noninflammatory joint pain.
Clinical Juvenile Arthritis Disease Activity Score Use in Treat-to-Target Therapy
November 29, 2017The objective of this study is to determine whether the JADAS or cJADAS would accurately predict patients with JIA in need of treatment escalation to anti-TNF after starting MTX.
Rheumatology Advisor Articles
- One-Session Intervention for Hand OA Improved Grip Strength, Patient Satisfaction
- Exercise, TNFi Provide Differential Benefits for Cardiovascular Health in Rheumatoid Arthritis
- Improving RA Diagnosis With Use of Anti-ACPAs
- Anti-Drug Antibody Incidence Risk in RA Increases Over Time With Adalimumab, Infliximab
- MBDA Scores Reflect Response to Rituximab Treatment in Rheumatoid Arthritis
- Circadian Rhythm in Rheumatoid Arthritis: Using Chronotherapy to Improve Outcomes
- Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?
- Examining Insurance Complications in the Shared Decision Making Process for Rheumatoid Arthritis
- Filgotinib Safe, Effective for Treatment of Active Ankylosing Spondylitis
- FDA Fast Track Designation Granted for Investigational Osteoarthritis Treatment
- Ultrasonography in Gout: Potential Applications for Diagnosis and Patient Monitoring
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information
- Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay
- Poor Vitamin K Status Linked to Low BMD, Increased Fracture Risk in ESRD
- Most Insured Patients Not Using Online Portals